In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin.
about
Efflux-mediated drug resistance in bacteria: an updateStructural and functional analysis of two glutamate racemase isozymes from Bacillus anthracis and implications for inhibitor designDesign and Synthesis of Aryl Ether Inhibitors of theBacillus AnthracisEnoyl-ACP ReductaseKinetic and X-Ray Structural Evidence for Negative Cooperativity in Substrate Binding to Nicotinate Mononucleotide Adenylyltransferase (NMAT) from Bacillus anthracisAlternative pre-approved and novel therapies for the treatment of anthraxConference report on public health and clinical guidelines for anthraxA Bacillus anthracis Genome Sequence from the Sverdlovsk 1979 Autopsy SpecimensMonoclonal antibody therapies against anthraxOptical Screening for Rapid Antimicrobial Susceptibility Testing and for Observation of Phenotypic Diversity among Strains of the Genetically Clonal Species Bacillus anthracisMolecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors.Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin.Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax modelRapid identification of genetic modifications in Bacillus anthracis using whole genome draft sequences generated by 454 pyrosequencing.Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolatesGenomewide screening for novel genetic variations associated with ciprofloxacin resistance in Bacillus anthracis.A rapid antimicrobial susceptibility test for Bacillus anthracis.New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV.Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridgeDeoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteriaActivity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.Antibodies against anthrax: mechanisms of action and clinical applications.Structure based in silico analysis of quinolone resistance in clinical isolates of Salmonella Typhi from India.Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.Efflux-mediated antimicrobial resistance.Identification of Genome-Wide Mutations in Ciprofloxacin-Resistant F. tularensis LVS Using Whole Genome Tiling Arrays and Next Generation SequencingDaptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrityPeptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis.Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents.Poly-γ-(D)-glutamic acid capsule interferes with lytic infection of Bacillus anthracis by B. anthracis-specific bacteriophagesFluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxRapid polymerase chain reaction-based screening assay for bacterial biothreat agentsAnti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.Humans and evolutionary and ecological forces shaped the phylogeography of recently emerged diseases
P2860
Q24609407-3BC26630-50E8-4A19-9BF2-3FF53993A8E7Q24643595-6820A04D-3F0E-45CF-92B1-921866996340Q27651378-9E2A93D6-4D9A-4624-9EFA-730F13503290Q27652732-337C8759-30F6-4B5D-B899-93D6128B4F37Q28075453-C34BB362-CE77-4510-906C-A0D4A560B054Q28386084-00168B4B-4CF5-4CAA-8701-A28F3D956885Q28390855-F5F0FB84-0C01-4FB1-B856-B17CE056B647Q28393072-8905191A-BDC6-4C0D-98F5-61B6742AD61CQ29248800-5D7FCDAE-BADB-4D7A-9B9B-CD85D733C5E8Q30570720-CA707A71-DF2A-47D3-ACC4-9D6B62C0E055Q33306246-55FD2BAF-330A-484A-9E7A-A4946533DF15Q33676316-2751337A-6D25-495A-A1C5-F5EDE1A611DEQ33682212-2118F405-DF72-4359-99C1-9266E4D6A5C1Q33836603-EDBC9C97-08C7-48E0-BB3F-C7EF67EE601EQ33962831-6F31C7DC-0CF7-4A32-97F2-CD1E3C4C9242Q33962839-36A68898-155D-414F-A5A1-D73C3BF6468DQ34066161-BF44954A-F268-4DD8-8272-4EE92AB35B4FQ34119765-BF48A29A-7C88-4D33-A0DF-A7B5491878C1Q34150994-D0CE7ED7-DEB1-492F-A353-D0AABE80D7E2Q34575393-CA09FF34-671C-41F9-B391-C20EFDA6D22DQ34597404-E7A8764D-DD24-4547-9F38-F74A157CC5F1Q35574888-365A5893-3530-4B7A-8BD5-2879F39EFD69Q35592636-9014D346-BBF8-4A32-9172-49D6BA6D50EFQ35610439-FB34A3B6-AEDF-4980-9AE1-57B5DBED94C3Q35626961-4A5354F2-D937-429B-94AA-17F1908828E5Q35682250-2CE767F7-E608-44B2-AEE6-67E955C2B23EQ36138147-BC595E80-DB3F-401A-9CA7-EB3DBD70FE02Q36144648-E39F874A-9F4E-4379-AD89-4092D201F1FCQ36295305-1BA6DC75-594D-481F-B848-2584737E80E9Q36297919-48AF4D35-B487-4AD9-A5A6-4F991F85D9AFQ36408717-BC26E587-C2C7-46F0-A06D-3EE2C4610CEDQ36558644-19A6E1DA-B555-4A59-8FBC-EBF37B6D29AAQ36607348-9B613D30-1E37-49A8-B22E-99AD75E3EDF5Q36669771-4E10E02B-6AD9-4CA2-8FC7-4E91E0E54BF2Q36783606-E9CF0E23-4EC0-4C36-B113-DF563E66B5D0Q36870766-4038E330-A7A5-4054-BA50-E62B6D018AC8Q36945830-0E4323FD-B10B-45B5-8187-05E919B4DE5FQ37262118-5F860726-5A23-4723-AAB1-A1977EB91B4FQ37407949-1A78C577-C463-4DE5-A44C-15A7BCDC0788Q37477193-4C75D5BE-5F47-46AA-9EA5-53656AAE1A2D
P2860
In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
In vitro selection and charact ...... l resistance to ciprofloxacin.
@en
In vitro selection and charact ...... l resistance to ciprofloxacin.
@nl
type
label
In vitro selection and charact ...... l resistance to ciprofloxacin.
@en
In vitro selection and charact ...... l resistance to ciprofloxacin.
@nl
prefLabel
In vitro selection and charact ...... l resistance to ciprofloxacin.
@en
In vitro selection and charact ...... l resistance to ciprofloxacin.
@nl
P2093
P2860
P1476
In vitro selection and charact ...... l resistance to ciprofloxacin.
@en
P2093
Amy Vogler
James M Schupp
Joseph D Busch
Lance B Price
P2860
P304
P356
10.1128/AAC.47.7.2362-2365.2003
P407
P577
2003-07-01T00:00:00Z